Research programme: Th17 antagonists - Allozyne
Alternative Names: AZ 17Latest Information Update: 16 Jul 2016
At a glance
- Originator Allozyne
- Class Bispecific antibodies
- Mechanism of Action Th17 cell inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Crohn's disease; Inflammation; Psoriasis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Crohn's-disease in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Psoriasis in USA (Parenteral)